PATENTS

Recent patents in antibody engineering Patent number Description Assignee Inventor Date US 9,184,781 Humanized, chimeric and human anti-CD20 antibodies Immunomedics Hansen H, Rossi E, 11/10/2015 and CD20 antibody fusion proteins that bind to a human (Morris Plains, NJ, USA) Chang C-HK, Goldenberg DM B-cell marker, referred to as CD20, useful for the treat- ment and diagnosis of B-cell disorders, such as B-cell malignancies and autoimmune diseases, and methods of treatment and diagnosis. US 9,181,349 Antibody-like binding proteins comprising four polypep- Sanofi (Paris) Baurin N, Biel C, Corvey C, 11/10/2015 tide chains that form four antigen binding sites, wherein Lange C, Li D, Mikol V, each pair of polypeptides forming an antibody-like bind- Steinmetz A, Rao E ing protein possesses dual variable domains having a cross-over orientation. Also, methods for making such antigen-like binding proteins. US 9,181,334 An antibody, or a fragment thereof, which has immuno- () Kobayashi S, Okano F, Saito T 11/10/2015 logical reactivity with a CAPRIN-1 protein, which targets a cancer antigenic protein specifically expressed on the surface of cancer cells, and use thereof as a therapeutic and/or preventive agent for cancer. US 9,181,346 A composition comprising a main species HER2 antibody Genentech (South Harris RJ, Motchnik PA 11/10/2015 that binds to domain II of HER2 and acidic variants San Francisco, CA, USA) thereof. Also, pharmaceutical formulations comprising the composition, and therapeutic uses for the composi- tion. US 9,181,344 The treatment of autoimmune diseases and disorders, in Genmab (Copenhagen) Losen M, Martinez-Martinez P, 11/10/2015 particular myasthenia gravis, by administration of effector De Baets MH, Graus Y, function–deficient antibodies, wherein said effector func- Schuurman J, Parren P tion–deficient antibodies are capable of competing with one or more of the autoantibodies involved in mediating the antibody-mediated autoimmune disease or disorder for binding to a target autoantigen. US 9,181,337 Modulated lysine variant species compositions compris- AbbVie (North Chicago, IL, Subramanian K, 11/10/2015 ing a protein, e.g., an antibody, or antigen-binding portion USA) Perez Thiele M, Zeng X, thereof, and methods, e.g., cell culture and/or protein Wong CF, Kaymakcalan Z, purification methods, for producing such modulated Jing Y, Chumsae C lysine variant species compositions. Also, methods for using such compositions to treat a disorder, e.g., a disor- der in which TNFa is detrimental. US 9,181,333 Antibodies that specifically bind human RSPO3 proteins OncoMed Pharmaceuticals Gurney AL, Bond CJ 11/10/2015 and modulate b-catenin activity; methods of using agents (Redwood City, CA, USA) that modulate the activity of RSPO3 proteins and inhibit tumor growth; and methods of treating cancer compris- ing administering a therapeutically effective amount of Nature America, Inc. All rights reserved. America, Inc. © 201 5 Nature an agent or antibody of the present invention to a patient having a tumor or cancer. US 9,181,332 An anti-Ab oligomer humanized antibody which does not Kyowa Hakko Kirin Co. Ltd. T, N 11/10/2015 bind to Ab monomers and specifically binds only to Ab (Tokyo) npg oligomers; an anti-cognitive-dysfunction agent, an agent for treating Alzheimer’s disease, an agent for suppressing formation of neuritic plaque and an inhibitor of formation of Ab amyloid fiber comprising the antibody as an active ingredient; a method for at least one of preventing and treating cognitive dysfunction or Alzheimer’s disease, comprising the step of administering the antibody; and a method for suppressing progression of Alzheimer’s dis- ease, comprising the step of administering the antibody.

US 9,175,080 An antibody that binds to a human PGE2 receptor NB Health Laboratory Co. Ltd. Takayama K, Shimizu T, 11/3/2015 subtype EP4 and inhibits the function of EP4, or a func- (Sapporo, ) Urushibata Y, Sugimoto Y tional fragment thereof, and a medicament comprising the aforementioned antibody or a functional fragment thereof. Sources: US Patent and Trademark Office (http://www.uspto.gov); European Patent Office (http://www.epo.org).

NATURE BIOTECHNOLOGY VOLUME 33 NUMBER 12 DECEMBER 2015 1235